There has already been considerable research devoted to developing immunotherapies which leverage FoxP3+ Tregs in the management of type I diabetes mellitus, systemic lupus erythematosus, and Crohn’s disease (33–35). The gene discussed is FOXP3; the disease is type 1 diabetes mellitus.